Status:
UNKNOWN
Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events
Lead Sponsor:
Grigore T. Popa University of Medicine and Pharmacy
Conditions:
Covid19
Corona Virus Infection
Eligibility:
All Genders
18+ years
Brief Summary
An estimated 22% of the global population is at an increased risk of a severe form of COVID-19, while one in four coronavirus patients admitted to intensive care unit will develop a pulmonary embolism...
Detailed Description
The study's protocol will cover the following steps: • Collected data from COVID-19 patients at admission will include: * Descriptive general demographic data * Previous pathologies and thrombosis r...
Eligibility Criteria
Inclusion
- All hospitalized patients with cough, fever, myalgia - with confirmed COVID-19 infection • All patients with a positive SARS-CoV-2 PCR test
Exclusion
- Patient refusal
- Uncertain tests results
- Children
Key Trial Info
Start Date :
August 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 18 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04519398
Start Date
August 18 2020
End Date
August 18 2021
Last Update
August 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Medicine and Pharmacy Gr T. Popa Iasi, Romania
Iași, Romania, 700503